Neoadjuvant Endocrine Therapy in Breast Cancer

WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancerПодробнее

FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of RecurrenceПодробнее

Axillary management for breast cancer in the post-neoadjuvant settingПодробнее

RxPONDER: chemotherapy and endocrine therapy in HR+/HER2- breast cancerПодробнее

How are lymph nodes assessed prior to treatment with neoadjuvant endocrine therapy or chemotherapy?Подробнее

Neoadjuvant and Adjuvant Treatment Considerations of ILC | Lobular Breast Cancer Event 2023Подробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Breast Cancer | Lec Endocrine Therapy | Terminology |NeoAdjuvant Therapy & Adjuvant TherapyПодробнее

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer GuidelineПодробнее

Adjuvant Therapy | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Adjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer Sandy Ruiz-Cruz, MDПодробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancerПодробнее

How to Treat Stage III (3) Breast Cancer - UpdatedПодробнее

The impact of the COVID-19 pandemic on the management of patients with breast cancerПодробнее

Composite biomarkers predictive of palbociclib + endocrine treatment benefit in early breast cancerПодробнее

The predictive value of treatment response after neoadjuvant therapyПодробнее

Updates in Systemic Therapy for Breast Cancer 2/8/23Подробнее

Exploring Neoadjuvant Therapy for Breast Cancer: What You Need to KnowПодробнее